Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study

Previous studies have shown that combining immune checkpoint inhibitors (ICIs) with talimogene laherparepvec (TVEC) may improve antitumor responses. However, the risk of developing cutaneous immune-related adverse events (cirAEs) in patients treated with ICI and TVEC has not been studied. To evaluat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the American Academy of Dermatology 2023-06, Vol.88 (6), p.1265-1270
Hauptverfasser:	Leung, Bonnie W., Wan, Guihong, Nguyen, Nga, Rashdan, Hannah, Zhang, Shijia, Chen, Wenxin, Cohen, Sonia, Boland, Genevieve M., Sullivan, Ryan J., Fadden, Riley M., Kaufman, Howard L., Kwatra, Shawn G., LeBoeuf, Nicole R., Semenov, Yevgeniy R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cohort Studies cutaneous immune-related adverse events cutaneous toxicities Humans immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects immunotherapy melanoma Melanoma - pathology Oncolytic Virotherapy - adverse effects Retrospective Studies skin cancer talimogene laherparepvec
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!